

To,

Date: 28.05.2019

1.) BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001.

2.) Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th Floor, Plot No. C62, Opp. Trident
Hotel, Bandrakurla Complex, Bandra (E), Mumbai-
400098

3.) Ahemdabad Stock Exchange Limited
Kamdhenu Complex, Opp. Sahajanad College,
Panjara Pole, Ambawadi, Ahmedabad - 380015

Dear Sir/Madam,

**Sub: Outcome of board meeting under regulation 30 read with 33 (3) (c) of SEBI
(Listing Obligations and Disclosure requirements) Regulations, 2015**

Ref: Dr. Habeebullah Life Sciences Ltd (Scrip code: 539267)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of Dr. Habeebullah Life Sciences Ltd held on Tuesday, the 28th day of May, 2019 at 3.00P.M. at the registered office of the Company the following were duly considered and approved by the Board:

1. Audited financial Statements (Standalone & Consolidated) for the quarter and year ended 31.03.2019.
2. The Auditor's Report on audited financial statements (Standalone & Consolidated) for the quarter and year ended 31.03.2019.

The meeting of the Board of Directors commenced at 3.00 P.M.(IST) and concluded at 5.00P.M.(IST).

This is for the information and records of the Exchange, please.


Thanking you.

Yours faithfully,
For Dr Habeebullah Life Sciences Ltd



K.Krishnam Raju
Whole-Time Director
(DIN: 00874650)


Encl: as above



Dr Habeebullah Life Sciences Ltd
(Formerly Known as PC Products India Limited)

PART II - AUDITED STANDALONE & CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR QUARTER IV AND YEAR ENDED 31ST MARCH, 2019

Particulars		STANDALONE FINANCIALS						CONSOLIDATED FINANCIALS	
		Quarter Ended			Year Ended			Year Ended	
		3 Months Ended 31/03/2019	Preceding 3 Months Ended 31/12/2018	Corsp. 3 months ended 31/03/2018	3/31/2019	3/31/2018	3/31/2019	3/31/2018	
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited	
I	Revenue from Operations	62.01	56.05	24.05	201.45	61.67	201.45	61.67	
II	Other Income	11.05	-	-	11.05	-	11.05	2.81	
III	Total Revenue (I+II)	73.05	56.05	24.05	212.49	61.67	212.49	64.49	
IV	Expenses								
	Cost of Material Consumed	9.69	5.23	4.54	23.00	6.41	23.00	6.41	
	Employee benefits expense	32.58	26.88	24.79	119.79	69.04	131.69	71.31	
	Depreciation and Amortisation expense	0.67	0.09	0.23	0.94	0.23	1.84	1.20	
	Other Expenses	76.21	69.98	30.23	282.31	88.15	290.80	96.69	
	Total Expenses	119.15	102.18	59.79	426.05	163.83	447.33	175.60	
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(46.09)	(46.13)	(35.74)	(213.55)	(102.15)	(234.84)	(111.12)	
VI	Exceptional Items	-	-	-	-	-	-	-	
VII	Profit/(Loss) before tax (V-VI)	(46.09)	(46.13)	(35.74)	(213.55)	(102.15)	(234.84)	(111.12)	
VIII	Tax Expense:								
	Current Tax	-	-	-	-	-	-	-	
	Deferred Tax	-	-	-	-	-	(2.68)	(6.22)	
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(46.09)	(46.13)	(35.74)	(213.55)	(102.15)	(232.16)	(104.90)	
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-	-	
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-	-	
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-	-	
XIII	Profit/ (Loss) for the period (IX+XII)	(46.09)	(46.13)	(35.74)	(213.55)	(102.15)	(232.16)	(104.90)	
XIV	Other Comprehensive Income								
	A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss								
	(B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss								
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(46.09)	(46.13)	(35.74)	(213.55)	(102.15)	(232.16)	(104.90)	
XVI	Comprehensive Income attributable to Non Controlling Interest	-	-	-	-	-	(9.06)	(1.34)	
XVII	Comprehensive Income attributable to Owners of the company	(46.09)	(46.13)	(35.74)	(213.55)	(102.15)	(223.11)	(103.56)	
XVIII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)								
	1) Basic	(0.38)	(0.38)	(0.34)	(1.75)	(0.96)	(1.83)	(0.97)	
	2) Diluted	(0.35)	(0.32)	(0.26)	(1.62)	(0.74)	(1.69)	(0.75)	
XIX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)								
	1) Basic	-	-	-	-	-	-	-	
	2) Diluted	-	-	-	-	-	-	-	
XX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)								
	1) Basic	(0.38)	(0.38)	(0.34)	(1.75)	(0.96)	(1.83)	(0.97)	
	2) Diluted	(0.35)	(0.32)	(0.26)	(1.62)	(0.74)	(1.69)	(0.75)	
XXI	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,380.87	1,221.37	1,175.87	1,380.87	1,175.87	1,380.87	1,175.87	
XXII	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	(142.23)	(142.23)	(190.07)	(142.23)	(190.07)	(192.59)	(239.03)	



Notes:

1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been prepared, reviewed by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Tuesday, 28th May, 2019.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. During the financial year the Company has converted 2050000 share warrants into fully paid Equity shares of Rs. 10 each, upon receipt of full payment of Rs. 15/- per share. These Share warrants were issued at a premium of Rs. 10. Consequently, as on 31st March 2019 1000000 Share Warrants are pending to be converted.
4. The Consolidated Financial Results includes the results of the Company and its Subsidiary - Krisani Bio Sciences Private Limited.
5. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
6. The figures of the current quarter ended 31st March, 2019 and the quarter ended 31st March, 2018 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
7. The Company has only one reportable segment i.e., **Health Care** Sector. Hence, the separate disclosure on Segment information is not required.
8. The results are also available on the website of the Company www.drhsl.com
9. The Audited Standalone Financials Results are summarised below:

Particulars	Quarter Ended 31-03-2019	Quarter Ended 31-12-18	Quarter Ended 31-03-18	Year Ended 31-03-19	Year Ended 31-03-18
Turnover	73.05	56.05	24.05	212.49	61.67
Profit Before Tax	(46.09)	(46.13)	(35.74)	(213.55)	(102.15)
Profit After Tax	(46.09)	(46.13)	(35.74)	(213.55)	(102.15)

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K Krishnam Raju
Executive Chairman(DIN 00874650)




Place : Hyderabad
Date :28-05-2019

Statement of Assets and Liabilities

(INR. in Lakhs)

Particulars	STANDALONE		CONSOLIDATED	
	31/03/2019	31/03/2018	31/03/2019	31/03/2018
ASSETS				
1 Non Current Assets				
a Property, Plant and Equipments	3.83	1.99	25.97	36.18
b Capital Work In Progress	-	-	-	-
c Investment Prpoerty	-	-	-	-
d Goodwill	-	-	-	-
e Other Intangible Assets	-	-	-	-
f Intangible Assets under development	214.55	91.66	1,776.70	1,613.33
g Biological assets other than bearer plants	-	-	-	-
h Financial Assets:	-	-	-	-
i Investments	487.06	487.06	0.75	0.75
ii Trade Receivables	-	-	-	-
iii Loans	-	-	-	-
iv Others	202.54	195.25	202.54	195.25
v Loans	-	-	-	-
vi Others	-	-	-	-
i Deferred Tax Assets (net)	-	-	38.99	36.31
j Other Non Current Assets	-	-	-	-
Total Non Current Assets	907.99	775.95	2,044.96	1,881.82
2 Current Assets				
a Inventories	15.92	9.52	15.92	9.52
b Financial Assets	-	-	-	-
i Investments	-	-	-	-
ii Trade Receivables	221.23	287.40	221.23	287.40
iii Cash and Cash Equivalents	1.50	33.23	2.30	34.48
iv Bank balances other than above	-	-	-	-
v Loans	94.00	70.00	94.00	70.00
vi Others	-	-	-	-
c Current Tax Assets (net)	-	-	-	-
d Other Current Assets	282.28	46.60	243.92	6.98
Total Current Assets	614.93	446.76	577.37	408.39
Total Assets	1,522.92	1,222.71	2,622.32	2,290.21
EQUITY AND LIABILITIES				
1 Equity				
a Equity Share Capital	1,380.87	1,175.87	1,380.87	1,175.87
b Other Equity	-	-	-	-
i Share Warrants	50.00	152.50	50.00	152.50
ii Reserves and Surplus	(150.78)	(142.23)	(210.70)	(192.59)
iii Non-Controlling Interests	-	-	405.00	414.06
Total - Equity	1,280.09	1,186.15	1,625.17	1,549.84



2 Liabilities				
Non Current Liabilities				
a Financial Liabilities	-	-	-	-
i Borrowings	-	-	-	-
ii Trade Payables	-	-	-	-
iii Other Financial Liabilities	-	-	-	-
b Provisions	12.57	5.93	12.57	5.93
c Deferred Tax Liabilities (net)	-	-	-	-
d Other Non Current Liabilities	-	-	-	-
Total Non Current Liabilities	12.57	5.93	12.57	5.93
Current Liabilities				
a Financial Liabilities				
i Borrowings	132.40	-	791.80	680.50
ii Trade Payables	23.99	6.21	23.99	6.21
iii Other Financial Liabilities	-	-	-	-
b Other Current Liabilities	73.10	24.11	168.02	47.41
c Provisions	0.76	0.33	0.76	0.33
d Current Tax Liabilities (net)	-	-	-	-
Total Current Liabilities	230.25	30.64	984.58	734.44
Total - Equity and Liabilities	1,522.92	1,222.71	2,622.32	2,290.21

For DR HABEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju

K. Krishnam Raju
Executive Chairman (DIN 00874650)



Place: Hyderabad
Date: 28-05-2019



& Associates

Chartered Accountants

1101/B, Manjeera Trinity Corporate,
JNTU-Hitech City Road, Kukatpally,
Hyderabad-500072, Telangana, INDIA
Tel: +91 40 6814 2999

**Auditor's Report On Quarterly Financial Results and Year to Date Financial Results of the Company
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

To the Board of Directors of DR HABEEBULLAH LIFE SCIENCES LIMITED

1. We have audited the accompanying Statement of Standalone Financial Results of DR HABEEBULLAH LIFE SCIENCES LIMITED ('the Company') for the quarter and year ended March 31, 2019 (the 'Statement'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The statement, as it relates to the quarter ended March 31, 2019, are the balancing figures between audited standalone figures in respect of the full financial year and the published standalone year to date figures up to the end of the third quarter of the financial year, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ('Ind AS 34'). The Statements also relates to the year ended March 31, 2019, has been prepared on the basis of the related standalone financial statements for the year ended March 31, 2019, prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India. This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. Our responsibility is to express an opinion on the Statement based on our audit of standalone financial statements for the year ended March 31, 2019 and our review of standalone financial results for the nine months period ended December 31, 2018.
3. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation of the Statement that give a fair presentation view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Statement.

Opinion

4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
 - ii. gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net loss, total comprehensive income and other financial information of the Company for the year ended March 31, 2019.

Other Matter

5. The comparative financial information of the company for the year ended March 31, 2018 prepared in accordance with Ind AS included in the Statement have been audited by the predecessor auditor who had audited the financial statements for the relevant periods. The report of the predecessor auditor dated May 30, 2018 on the comparative financial information for the year ended March 31, 2018 expressed an unmodified audit opinion with respect to such comparative financial information.


Our opinion is not modified in respect of these matters.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No.105047W


Ananthakrishnan G
Partner
Membership No.: 205226



Place: Hyderabad

Date:28-05-2019



& Associates

Chartered Accountants

1101/B, Manjeera Trinity Corporate,
JNTU-Hitech City Road, Kukatpally,
Hyderabad-500072, Telangana, INDIA
Tel: +91 40 6814 2999

Auditor's Report On Quarterly Consolidated Financial Results and Consolidated Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of DR HABEEBULLAH LIFE SCIENCES LIMITED

1. We have audited the accompanying Statement of Consolidated Financial Results of DR HABEEBULLAH LIFE SCIENCES LIMITED (the 'Company') and its subsidiary (the Company and its subsidiaries together referred to as "the Group") for the year ended March 31, 2019 (the 'Statement') , being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The statement, as it relates to the quarter ended March 31, 2019, are the balancing figures between audited consolidated figures in respect of the full financial year and the published consolidated year to date figures up to the end of the third quarter of the financial year, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ('Ind AS 34'). The Statements also relates to the year ended March 31, 2019, has been prepared on the basis of the related consolidated financial statements for the year ended March 31, 2019, prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India. This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. Our responsibility is to express an opinion on the Statement based on our audit of consolidated financial statements for the year ended March 31, 2019 and our review of consolidated financial results for the nine months period ended December 31, 2018.
3. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act . Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation of the Statement that give a fair presentation view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the

effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in the paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the Statement.

4. We did not audit financial statements of subsidiary company, whose financial statements reflect total assets of Rs. 16,26,46,564 as at March 31, 2019 (year to date), total revenues of Nil as at March 31, 2019 (year to date), as considered in the Statement. The financial statements of the subsidiary have been audited by the other auditors whose reports have been furnished to us by the management, and our opinion on this Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, and our report in terms of sub-section (3) of Section 143 of the Act, insofar as it relates to the aforesaid subsidiary, is based solely on the report of other auditors.

Opinion

5. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - i. includes the financial results of the following entities:
 - a. Krisani Bio Sciences Private Limited (Subsidiary)
 - ii. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
 - iii. gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net loss, total comprehensive income and other financial information of the Group for the year ended March 31, 2019.

Other Matter

6. The comparative financial information of the Group for the year ended March 31, 2018 prepared in accordance with Ind AS included in the Statement have been audited by the predecessor auditor who had audited the financial statements for the relevant periods. The report of the predecessor auditor



dated May 30, 2018 on the comparative financial information for the year ended March 31, 2018 expressed an unmodified audit opinion with respect to such comparative financial information.

Our opinion is not modified in respect of these matters.

For MSKA & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Ananthakrishnan G
Partner
Membership No.: 205226



Place: Hyderabad
Date:28-05-2019

To,

Date: 28.05.2019

1.) BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001.

2.) Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th Floor, Plot No. C62, Opp. Trident Hotel,
Bandrakurla Complex, Bandra (E), Mumbai-400098

3.) Ahmedabad Stock Exchange Limited
Kamdhenu Complex, Opp. Sahajanad College,
Panjara Pole, Ambawadi, Ahmedabad - 380015

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.

Ref: Scrip Code - 539267

I, K.Krishnam Raju, Whole-Time Director of Dr Habeebullah Life Sciences Ltd hereby declare that, the Statutory Auditors of the company, M/s. MSKA & Associates., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2019.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide. Circular No. No.CIR/CFD/CMD/56/2016 dated 27-05-2016.

Thanking you,

Yours faithfully,

For Dr Habeebullah Life Sciences Ltd


K.Krishnam Raju
Whole-Time Director
(DIN: 00874650)



Dr Habeebullah Life Sciences Ltd
(Formerly Known as PC Products India Limited)

Regd.Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad - 500048. TS.India

Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad - 500008.TS. India

CIN No. : L85110TG1996PLC099198

Email : info@drhsl.com, pproductsindia@gmail.com

Contact No.: 040 - 2970 3333, +91 9030057370

Website : www.drhsl.com